Tom Brinkmann serves as the Associate Director of Finance at Cirtec Medical, a prominent medical device manufacturer generating $200 million in annual sales and backed by private equity. In this pivotal role, Tom leverages his extensive expertise in financial planning and analysis (FP&A), pricing optimization,...
Tom Brinkmann serves as the Associate Director of Finance at Cirtec Medical, a prominent medical device manufacturer generating $200 million in annual sales and backed by private equity. In this pivotal role, Tom leverages his extensive expertise in financial planning and analysis (FP&A), pricing optimization, and data analytics to drive strategic initiatives that enhance the company’s financial performance. His collaborative approach has been instrumental in working alongside the CEO to implement strategic price increases, successfully elevating the EBITDA margin from 25% to 29%.
Tom’s proficiency in financial modeling and the development of monthly dashboards and key performance indicators (KPIs) ensures that senior management is equipped with actionable insights for informed decision-making. His commitment to supporting the monthly close process and spearheading cost-saving initiatives has not only streamlined operations but also contributed significantly to the company’s bottom line.
With a proven track record of raising sales growth from 6.5% to 11%, Tom excels in cross-functional partnerships, effectively aligning finance with sales and marketing strategies. His skills in competitive pricing and business intelligence, complemented by his proficiency in tools like Tableau, empower him to conduct thorough market research and analytics, driving data-driven financial analysis that informs strategic direction. Tom’s passion for staff development further enhances his leadership, fostering a culture of continuous improvement and collaboration within the finance team. In an industry where precision and innovation are paramount, Tom Brinkmann stands out as a key contributor to Cirtec Medical’s ongoing success and growth.
